Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial

Gynecologic Oncology

Volumn 144, Issue 1, 2017, Pages 51-56

  Wright, Thomas C ^a   Behrens, Catherine M ^b   Ranger Moore, James ^c   Rehm, Susanne ^c,d   Sharma, Abha ^b   Stoler, Mark H ^e   Ridder, Ruediger ^c,d  

^a Columbia University ^*  (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d Roche Mtm Laboratories   (Germany)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

ATHENA; Cervical cancer screening; CINtec PLUS; Genotyping; HPV; p16 Ki 67 dual stained cytology; Triage

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16; CYCLIN DEPENDENT KINASE INHIBITOR 2A; P16 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GRADING; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOLOGY; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENETICS; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VAGINA SMEAR; VIROLOGY;

ADULT; BIOPSY; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CLINICAL TRIALS AS TOPIC; COLPOSCOPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENOTYPE; HUMANS; KI-67 ANTIGEN; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 85005965385     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.10.031     Document Type: Article

References (26)

1. [1] Schiffman, M., Wentzensen, N., Transitioning to a new era in cervical cancer screening. Gynecol. Oncol. 136 (2015), 175–177.
2. [2] Wentzensen, N., Schiffman, M., Palmer, T., Arbyn, M., Triage of HPV positive women in cervical cancer screening. J. Clin. Virol. 76:Suppl. 1 (2016), S49–S55.
3. [3] Wright, T.C., Stoler, M.H., Behrens, C.M., Sharma, A., Zhang, G., Wright, T.L., Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 136 (2015), 189–197.
4. [4] Huh, W.K., Ault, K.A., Chelmow, D., Davey, D.D., Goulart, R.A., Garcia, F.A., Kinney, W.K., Massad, L.S., Mayeaux, E.J., Saslow, D., Schiffman, M., Wentzensen, N., Lawson, H.W., Einstein, M.H., Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol. Oncol. 136 (2015), 178–182.
5. [5] Massad, L.S., Einstein, M.H., Huh, W.K., Katki, H.A., Kinney, W.K., Schiffman, M., Solomon, D., Wentzensen, N., Lawson, H.W., 2012 ASCCP Consensus Guidelines Conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet. Gynecol. 121 (2013), 829–846.
6. [6] Petry, K.U., Schmidt, D., Scherbring, S., Luyten, A., Reinecke-Lüthge, A., Bergeron, C., Kommoss, F., Löning, T., Ordi, J., Regauer, S., Ridder, R., Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol. Oncol. 121 (2011), 505–509.
7. [7] Wentzensen, N., Fetterman, B., Castle, P.E., Schiffman, M., Wood, S.N., Stiemerling, E., Tokugawa, D., Bodelon, C., Poitras, N., Lorey, T., Kinney, W., p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J. Natl. Cancer Inst., 107(12), 2015, djv257, 10.1093/jnci/djv257.
8. [8] Wentzensen, N., von Knebel Doeberitz, M., Biomarkers in cervical cancer screening. Dis. Markers 23 (2007), 315–330.
9. [9] Wentzensen, N., Fetterman, B., Tokugawa, D., Schiffman, M., Castle, P.E., Wood, S.N., Stiemerling, E., Poitras, N., Lorey, T., Kinney, W., Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol. 122 (2014), 914–920.
10. [10] Ikenberg, H., Bergeron, C., Schmidt, D., Griesser, H., Alameda, F., Angeloni, C., Bogers, J., Dachez, R., Denton, K., Hariri, J., Keller, T., von Knebel Doeberitz, M., Neumann, H.H., Puig-Tintore, L.M., Sideri, M., Rehm, S., Ridder, R., PALMS Study Group, Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J. Natl. Cancer Inst. 105 (2013), 1550–1557.
11. [11] Schmidt, D., Bergeron, C., Denton, K.J., Ridder, R., European CINtec Cytology Study Group, p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 119 (2011), 158–166.
12. [12] Wentzensen, N., Schwartz, L., Zuna, R.E., Smith, K., Mathews, C., Gold, M.A., Allen, R.A., Zhang, R., Dunn, S.T., Walker, J.L., Schiffman, M., Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin. Cancer Res. 18 (2012), 4154–4162.
13. [13] Donà, M.G., Vocaturo, A., Giuliani, M., Ronchetti, L., Rollo, F., Pescarmona, E., Carosi, M., Vocaturo, G., Benevolo, M., p16/Ki-67 dual staining in cervico-vaginal cytology: correlation with histology, human papillomavirus detection and genotyping in women undergoing colposcopy. Gynecol. Oncol. 126 (2012), 198–202.
14. [14] Roelens, J., Reuschenbach, M., von Knebel Doeberitz, M., Wentzensen, N., Bergeron, C., Arbyn, M., p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities. Cancer Cytopathol. 120 (2012), 294–307.
15. [15] Uijterwaal, M.H., Witte, B.I., Van Kemenade, F.J., Rijkaart, D., Ridder, R., Berkhof, J., der Meij GA, B.-v., Bleeker, M.C., Snijders, P.J., Meijer, C.J., Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br. J. Cancer 110 (2014), 1579–1586.
16. [16] Bergeron, C., Ikenberg, H., Sideri, M., Denton, K., Bogers, J., Schmidt, D., Alameda, F., Keller, T., Rehm, S., Ridder, R., PALMS Study Group, Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 123 (2015), 373–381.
17. [17] Uijterwaal, M.H., Polman, N.J., Witte, B.I., van Kemenade, F.J., Rijkaart, D., Berkhof, J., der Meij GA, B.-v., Ridder, R., PJ, S., CJ, M., Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int. J. Cancer 136 (2015), 2361–2368.
18. [18] Allia, E., Ronco, G., Coccia, A., Luparia, P., Macrì, L., Fiorito, C., Maletta, F., Deambrogio, C., Tunesi, S., De Marco, L., Gillio-Tos, A., Sapino, A., Ghiringhello, B., Interpretation of p16(INK4a)/Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology. Cancer Cytopathol. 123 (2015), 212–218.
19. [19] Rossi, P., Borghi, L., Ferro, R., Mencarelli, R., A population of 1136 HPV DNA-HR positive women: expression of p16(INK4a)/Ki67 dual-stain cytology and cytological diagnosis. Histological correlations and cytological follow up. Pathologica 107 (2015), 185–191.
20. [20] Gustinucci, D., Giorgi Rossi, P., Cesarini, E., Broccolini, M., Bulletti, S., Carlani, A., D'angelo, V., D'amico, M.R., Di Dato, E., Galeazzi, P., Malaspina, M., Martinelli, N., Spita, N., Tintori, B., Giaimo, M.D., Passamonti, B., Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening. Am. J. Clin. Pathol. 145 (2016), 35–45.
21. [21] Wright, T.C. Jr., Stoler, M.H., Behrens, C.M., Apple, R., Derion, T., Wright, T.L., The ATHENA human papillomavirus study: design, methods, and baseline results. Am. J. Obstet. Gynecol. 206 (2012), 46.e1–46.e11.
22. [22] Wright, T.C. Jr., Stoler, M.H., Sharma, A., Zhang, G., Behrens, C., Wright, T.L., ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group, Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV + cytology-negative results. Am. J. Clin. Pathol. 136 (2011), 578–586.
23. [23] Castle, P.E., Stoler, M.H., Wright, T.C. Jr., Sharma, A., Wright, T.L., Behrens, C.M., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 12 (2011), 880–890.
24. [24] Cox, J.T., Castle, P.E., Behrens, C.M., Sharma, A., Wright, T.C. Jr., Cuzick, J., Athena HPV Study Group, Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am. J. Obstet. Gynecol., 208, 2013 (184.e1-11).
25. [25] Solomon, D., Davey, D., Kurman, R., et al. The 2001 Bethesda system. Terminology for reporting results of cervical cytology. JAMA 287 (2002), 2114–2119.
26. [26] Wright, T.C. Jr., Stoler, M.H., Aslam, S., Behrens, C.M., Knowledge of patients' human papillomavirus status at the time of cytologic review significantly affects the performance of cervical cytology in the ATHENA study. Am. J. Clin. Pathol. 146 (2016), 391–398.